Trial Profile
An Open-Label Study of the Safety and Clinical Pharmacology of Stanate in Infants At-Risk for Exchange Transfusion
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Stannsoporfin (Primary)
- Indications Hyperbilirubinaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors InfaCare Pharmaceutical Corporation; Mallinckrodt plc
- 10 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Feb 2014 New trial record